For children with hemophilia, every new research advance is a step toward a life filled with more activity, freedom, and adventure. The genetic condition, which affects roughly one in 5,000 births, causes children to bleed and bruise more easily than others – meaning that a simple cut, scrape, or small surgery can result in uncontrollable and excessive bleeding. While hemophilia is a lifelong condition, breakthroughs in the laboratory are driving novel treatments, and thanks to recently announced grants from the Bayer Hemophilia Awards Program (BHAP), scientists at Children’s Hospital of Philadelphia will be able to continue conducting even more investigations.
Tag Archive: hemophilia
Training the next generation of investigators has long been a priority at Children’s Hospital of Philadelphia. There are numerous opportunities throughout the year to celebrate the accomplishments of our trainees and honor their commitment to science.
Your holiday season has been hectic, no doubt. Catch up with an early gift from us: Our biweekly roundup of research news from Children’s Hospital of Philadelphia comes with all the trimmings!
Buckle your seatbelts because this has been a busy week for research news at Children’s Hospital of Philadelphia.
Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated animals with the bleeding disorder hemophilia.
The Children’s Hospital of Philadelphia’s Lacramioara Ivanciu, PhD, was one of five investigators who recently received funding through the Bayer Hemophilia Awards Program (BHAP).
For her pioneering hemophilia and gene therapy research, Children’s Hospital hematologist Katherine A. High, MD, director of the Center for Cellular and Molecular Therapeutics (CCMT), was recently honored with the 2013 E. Donnall Thomas Lecture and Prize at the American Society of Hematology (ASH) Annual Meeting.